Amgen (AMGN) closed the most recent trading day at $385.65, moving +1.55% from the previous trading session. The stock ...

In the latest close session, Amgen (AMGN) was down 2.25% at $382.47. This change lagged the S&P 500's 0.59% loss on the day. Meanwhile, the Dow experienced a drop of 0.6%, and the technology-dominated ...

Amgen’s updated analyst model now points to a fair value price target of US$388.03, compared with the prior US$371.93. This provides a slightly higher anchor for how the stock is being valued today.

Amgen (AMGN) stock drops after a phase 3 trial failure for a heart drug from Novartis (NVS) and Ionis Pharma (IONS). BMO ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

Amgen (AMGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Amgen ( AMGN) dropped just over 10% on Tuesday after a late-stage cardiovascular trial failure at Novartis raised concerns ...

Amgen (AMGN) demonstrates defensive capabilities that endure through economic cycles by virtue of its portfolio of ...

In terms of shares owned, we count 1 of the above funds having increased existing AMGN positions from 03/31/2025 to 06/30/2025, with 7 having decreased their positions. Looking beyond these particular ...

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Amgen, with a price target of $435.00. According to TipRanks, Bansal is a 5-star analyst with an average return of ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.